Status:
COMPLETED
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The study was a three-arm, active-control, multi-centre, parallel group study.
Eligibility Criteria
Inclusion
- Main Inclusion Criteria:
- Patients, aged 18 years or over, with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
- Baseline testosterone \>1.5 ng/mL.
- Life expectancy of at least 12 months.
Exclusion
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
620 Patients enrolled
Trial Details
Trial ID
NCT00295750
Start Date
February 1 2006
End Date
October 1 2007
Last Update
December 19 2012
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
2
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States, 99508
3
Advanced Urology Medical Center
Anaheim, California, United States, 92801
4
Pacific Clinical Center
Beverly Hills, California, United States, 90210